Anti-Human ADAMTS13 Antibody (3H9)

Catalog No.

RHJ12101

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, lambda

Clonality

Monoclonal

Target

A disintegrin and metalloproteinase with thrombospondin motifs 13, ADAM-TS 13, ADAM-TS13, ADAMTS-13, 3.4.24.87, von Willebrand factor-cleaving protease, vWF-CP, vWF-cleaving protease, ADAMTS13, C9orf8, UNQ6102/PRO20085

Concentration

0.57 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q76LX8

Applications

Blocking, ELISA, FCM, SPR

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

3H9

Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study., PMID:40508203

Hemolytic uremic syndrome in severe acute pancreatitis., PMID:40443860

Immune Thrombotic Thrombocytopenic Purpura: A Review., PMID:40388146

PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910

Thrombotic thrombocytopenic purpura following plastic surgery: A case report., PMID:40340206

Pregnancy-related Thrombotic Microangiopathy has a spectrum of underlying causes., PMID:40306205

Soluble P-selectin, but not circulating cell-free DNA, is a potential diagnostic biomarker in heparin-induced thrombocytopenia., PMID:40252846

Agents of shield: glycans mask antibody epitopes on ADAMTS13., PMID:40198202

A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021., PMID:40145682

Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura., PMID:40136473

Atypical presentation of H1N1-induced thrombotic microangiopathy with CD46 gene mutation
., PMID:40115863

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy., PMID:40105947

[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]., PMID:40059685

[Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review]., PMID:40032339

Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report., PMID:40029564

The third form of thrombotic thrombocytopenic purpura shows up again: what is it, does it even exist, how to find out? Comment on "Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism" and on "The different faces of thrombotic thrombocytopenic purpura"., PMID:40013401

Immune-mediated TTP secondary to checkpoint inhibitor use in a patient with stage IV melanoma., PMID:40000048

Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review., PMID:39997466

Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura., PMID:39995752

Guidance-Based Appropriateness of Hemostasis Testing in the Acute Setting., PMID:39970900

Raising Suspicion of Thrombotic Thrombocytopenic Purpura in a Patient With a Pre-existing Autoimmune Disease., PMID:39963616

Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura., PMID:39956431

A case of thrombotic thrombocytopenic purpura induced by acute hepatitis E and successfully controlled by lymphoplasmapheresis plus rituximab., PMID:39955583

Impact of new medications on the treatment of immune TTP., PMID:39912777

Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review., PMID:39883995

More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on "Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism" and on "The different faces of thrombotic thrombocytopenic purpura"., PMID:39882652

Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis., PMID:39849814

[Not Available]., PMID:39835860

N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP., PMID:39813625

GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura., PMID:39794345

Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS., PMID:39774799

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange., PMID:39687921

A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies., PMID:39662872

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era., PMID:39626301

Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura., PMID:39624585

Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study., PMID:39518700

Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency., PMID:39511768

[Acquired thrombotic thrombocytopenic purpura with rituximab-induced serum sickness]., PMID:39505551

[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?]., PMID:39504978

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond., PMID:39467573

Refining the standard of care in immune thrombotic thrombocytopenic purpura., PMID:39356816

Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism., PMID:39323409

Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura., PMID:39293938

Legionella Pneumophila Presenting as a Rare Cause of Acute Thrombocytopenia: A Case Report and Review of Literature., PMID:39247236

Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura., PMID:39228246

A comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura., PMID:39221447

The Phenomenon of Thrombotic Microangiopathy in Cancer Patients., PMID:39201740

TTP and pregnancy., PMID:39197429

Pulmonary Tuberculosis Complicated by Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review., PMID:39171084

Document Download

Anti-Human ADAMTS13 Antibody (3H9).pdf